Anne Sonet

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Gilles Salles, John F. Seymour, Fritz Offner et al. · The Lancet · 2010 · 1.1K citations

Lymphoid Neoplasia, Oncology, Phase 3 +8

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

Emmanuel Bachy, John F. Seymour, Pierre Feugier et al. · Journal of Clinical Oncology · 2019 · 266 citations · Full text

Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial

Johan Maertens, Galia Rahav, Dong‐Gun Lee et al. · The Lancet · 2021 · 257 citations · Full text

Invasive Aspergillosis, Posaconazole Versus Voriconazole, Antifungal Agent +5

High Numbers of Tumor-Associated Macrophages Have an Adverse Prognostic Value That Can Be Circumvented by Rituximab in Patients With Follicular Lymphoma Enrolled Onto the GELA-GOELAMS FL-2000 Trial

Danielle Canioni, Gilles Salles, Nicolas Mounier et al. · Journal of Clinical Oncology · 2007 · 245 citations

Efficacy and Safety of Rasburicase (recombinant urate oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin’s Lymphoma: Results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study

Bertrand Coiffier, Nicolas Mounier, Serge Bologna et al. · Journal of Clinical Oncology · 2003 · 238 citations